C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT ID: NCT06868264
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
880 participants
INTERVENTIONAL
2025-04-07
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
NCT02201953
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05904470
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
NCT02996682
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
NCT02220998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Bemnifosbuvir-Ruzasvir (BEM/RZR)
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
Sofosbuvir-Velpatasvir (SOF/VEL)
Sofosbuvir-Velpatasvir (SOF/VEL)
SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bemnifosbuvir-Ruzasvir (BEM/RZR)
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
Sofosbuvir-Velpatasvir (SOF/VEL)
SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV)
* Documented medical history compatible with chronic HCV
* Either no liver cirrhosis or with compensated liver cirrhosis
* If HIV-1-positive, must meet the following 2 criteria:
1. Antiretroviral (ARV) regimen for \>8 weeks prior to screening visit, with CD4 T-cell count \>200 cells/mm3 and plasma HIV-1 RNA \<LLOQ
2. Suitable ARV treatment and not taking any contraindicated medications
Exclusion Criteria
* Co-infected with hepatitis B virus
* Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
* Requirement of any prohibited medications
* Use of other investigational drugs within 30 days of dosing
* History or signs of decompensated liver disease (decompensated cirrhosis)
* History of hepatocellular carcinoma (HCC)
* Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atea Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atea Study Site
Birmingham, Alabama, United States
Atea Study Site
Dothan, Alabama, United States
Atea Study Site
Chandler, Arizona, United States
Atea Study Site
Flagstaff, Arizona, United States
Atea Study Site
Mesa, Arizona, United States
Atea Study Site
Phoenix, Arizona, United States
Atea Study Site
Phoenix, Arizona, United States
Atea Study Site
Tucson, Arizona, United States
Atea Study Site
Little Rock, Arkansas, United States
Atea Study Site
Bakersfield, California, United States
Atea Study Site
Coronado, California, United States
Atea Study Site
Escondido, California, United States
Atea Study Site
Fresno, California, United States
Atea Study Site
Long Beach, California, United States
Atea Study Site
Los Angeles, California, United States
Atea Study Site
Los Angeles, California, United States
Atea Study Site
Orange, California, United States
Atea Study Site
Pasadena, California, United States
Atea Study Site
Sacramento, California, United States
Atea Study Site
Torrance, California, United States
Atea Study Site
Valencia, California, United States
Atea Study Site
Colorado Springs, Colorado, United States
Atea Study Site
Washington D.C., District of Columbia, United States
Atea Study Site
Washington D.C., District of Columbia, United States
Atea Study Site
Coral Gables, Florida, United States
Atea Study Site
DeLand, Florida, United States
Atea Study Site
Fort Lauderdale, Florida, United States
Atea Study Site
Ft. Pierce, Florida, United States
Atea Study Site
Gainesville, Florida, United States
Atea Study Site
Inverness, Florida, United States
Atea Study Site
Jupiter, Florida, United States
Atea Study Site
Lauderdale Lakes, Florida, United States
Atea Study Site
Maitland, Florida, United States
Atea Study Site
Miami, Florida, United States
Atea Study Site
Miami Lakes, Florida, United States
Atea Study Site
Orlando, Florida, United States
Atea Study Site
Pembroke Pines, Florida, United States
Atea Study Site
Sarasota, Florida, United States
Atea Study Site
West Palm Beach, Florida, United States
Atea Study Site
Macon, Georgia, United States
Atea Study Site
Marietta, Georgia, United States
Atea Study Site
Chicago, Illinois, United States
Atea Study Site
New Albany, Indiana, United States
Atea Study Site
Fairway, Kansas, United States
Atea Study Site
Topeka, Kansas, United States
Atea Study Site
Louisville, Kentucky, United States
Atea Study Site
New Iberia, Louisiana, United States
Atea Study Site
New Orleans, Louisiana, United States
Atea Study Site
Baltimore, Maryland, United States
Atea Study Site
Baltimore, Maryland, United States
Atea Study Site
Boston, Massachusetts, United States
Atea Study Site
Boston, Massachusetts, United States
Atea Study Site
Springfield, Massachusetts, United States
Atea Study Site
Worcester, Massachusetts, United States
Atea Study Site
Detroit, Michigan, United States
Atea Study Site
Grosse Pointe Woods, Michigan, United States
Atea Study Site
Novi, Michigan, United States
Atea Study Site
Wyoming, Michigan, United States
Atea Study Site
Tupelo, Mississippi, United States
Atea Study Site
Camden, New Jersey, United States
Atea Study Site
Hackensack, New Jersey, United States
Atea Study Site
Hillsborough, New Jersey, United States
Atea Study Site
Newark, New Jersey, United States
Atea Study Site
Newark, New Jersey, United States
Atea Study Site
Brooklyn, New York, United States
Atea Study Site
New York, New York, United States
Atea Study Site
Yonkers, New York, United States
Atea Study Site
Asheville, North Carolina, United States
Atea Study Site
Charlotte, North Carolina, United States
Atea Study Site
Fayetteville, North Carolina, United States
Atea Study Site
Beavercreek, Ohio, United States
Atea Study Site
Cincinnati, Ohio, United States
Atea Study Site
Tulsa, Oklahoma, United States
Atea Study Site
Allentown, Pennsylvania, United States
Atea Study Site
DuBois, Pennsylvania, United States
Atea Study Site
Philadelphia, Pennsylvania, United States
Atea Study Site
Philadelphia, Pennsylvania, United States
Atea Study Site
Charleston, South Carolina, United States
Atea Study Site
Chattanooga, Tennessee, United States
Atea Study Site
Cordova, Tennessee, United States
Atea Study Site
Jackson, Tennessee, United States
Atea Study Site
Arlington, Texas, United States
Atea Study Site
Dallas, Texas, United States
Atea Study Site
Dallas, Texas, United States
Atea Study Site
Denison, Texas, United States
Atea Study Site
Houston, Texas, United States
Atea Study Site
Plano, Texas, United States
Atea Study Site
San Antonio, Texas, United States
Atea Study Site
Temple, Texas, United States
Atea Study Site
Waco, Texas, United States
Atea Study Site
Ogden, Utah, United States
Atea Study Site
Chesapeake, Virginia, United States
Atea Study Site
Norfolk, Virginia, United States
Atea Study Site
Richmond, Virginia, United States
Atea Study Site
Richmond, Virginia, United States
Atea Study Site
Seattle, Washington, United States
Atea Study Site
Vancouver, British Columbia, Canada
Atea Study Site
Moncton, New Brunswick, Canada
Atea Study Site
St. John's, Newfoundland and Labrador, Canada
Atea Study Site
Brampton, Ontario, Canada
Atea Study Site
Ottawa, Ontario, Canada
Atea Study Site
Toronto, Ontario, Canada
Atea Study Site
Montreal, Quebec, Canada
Atea Study Site
Québec, Quebec, Canada
Atea Study Site
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AT-01B-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.